151 results about "Cerebrovascular disorder" patented technology

The invention provides compounds of the formula:wherein the ring A is an optionally substituted benzene ring; R1 is an optionally substituted non-aromatic heterocyclic group; R2 and R3 are independently hydrogen atom or an optionally substituted hydrocarbon group; n is an integer of 0-3; or salts thereof, which are useful as medicines having an osteogenesis promoting effect and chondrogensis promoting effect.The present invention relates to an amine compound having an excellent effect of inhibiting production and/or secretion of amyloid-b protein, a production and use thereof. Especially, it is effective for preventing and/or treating, for example, neurodegenerative diseases, amyloid angiopathy, neurological disorders caused by cerebrovascular disorders, and so forth.

The present invention provides a therapeutic agent containing as an active ingredient an HGF gene used for therapy of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, spinal cord injury, diabetic peripheral neuritis, and ischemic cerebrovascular disorders (cerebral infarction, cerebral haemorrhage, etc.) More specifically, the present invention provides a therapeutic agent for neurodegenerative diseases, containing a hepatocyte growth factor (HGF) gene as an active ingredient.

A pharmaceutical composition comprising at least one of components (a) and at least one of components (b) shown in below: (a) a compound represented by the general formula (I) (wherein R1 represents a hydrogen atom or a hydroxyl group) or an acid addition salt or hydrate thereof; and (b) an ameliorant of cerebral circulation, a vasodilator, a cerebral protecting drug, an brain metabolic stimulants, an anticoagulant, an antiplatelet drug, a thrombolytic drug, an amelirant of psychiatric symptom, a antihypertensive drug, an antianginal drug, a diuretic, a cardiotonic, an antiarrhythmic drug, an antihyperlipidemic drug, an immunosuppressant, or a pharmaceutically acceptable salt (except the components shown in (a)). It is useful as a preventive or remedy for cerebrovascular disorders and cardiac diseases.

The invention belongs to the medicine technical filed, in particular to a preparation method of monomeric compound ginsenoside Rg1, ginsenoside Rb1 and total arasaponin and the application in the medicine field thereof. The fresh medicinal material, the dried medicinal material and the medicinal material on the market of Panax notoginseng are taken as the raw materials; according to the polarity and the solubility property of a compound, separation and purification are carried out by adopting the solvent extraction method, the crystallization process and the chromatography and total arasaponin powder is prepared by combining the common drying means, such as decompression concentration drying, freeze drying, vacuum drying and the like; by carrying out one or more methods of recrystal, normal phase, opposite phase silica gel column chromatography, daiamid column chromatography and sephadex chromatography and the like on the powder, the ginsenoside Rg1 and the ginsenoside Rb1 monomers are prepared. The medicines which take the ginsenoside Rg1 and the ginsenoside Rb1 monomers or the total arasaponin as the active ingredients can be used for preventing and/or curing the senile dementia, the neurodegenerative diseases, the cerebrovascular disorder, various dysmnesia, the central lesion and other diseases.

The present invention describes novel nitrosated and/or nitrosylated potassium channel activators, and novel compositions comprising at least one nitrosated and/or nitrosylated potassium channel activator, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one potassium channel activator, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cardiovascular disorders, cerebrovascular disorders, hypertension, asthma, baldness, urinary incontinence, epilepsy, sleep disorders, gastrointestinal disorders, migraines, irritable bowel syndrome and sensitive skin.

The invention relates to a medicinal composition, which consists of the following parts: a calcium ion antagonist (CCB) or pharmaceutically acceptable salt thereof, an angiotensin II acceptor antagonist (ARB) or pharmaceutically acceptable salt or ester thereof, statins or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention also relates to a combined kit containing the active substances. The medicinal composition or the kit is used for treating hypertension, dyslipidemia, cerebrovascular disorder, stroke, coronary heart disease, diabetes, diabetic complication, angina, myocardial infarction, cardiac insufficiency, renal dysfunction, atherosclerosis, ventricular hypertrophy, aneurysm, myocardial ischemia, arrhythmia and glaucoma of patients, reducing the incidence rate and/or the death rate of cardiovascular and cerebrovascular disease, improving the adaptability of drug administration of the patients at the same time, and improving the life quality of the patients.

By introducing hepatocyte growth factor (HGF) gene and/or vascular endothelial growth factor (VEGF) gene into the subarachnoid space in humans, cerebrovascular disorders such as cerebrovascular obstruction, cerebral infarction, cerebral thrombosis, cerebral embolism, stroke, cerebral bleeding, moyamoya disease, cerebrovascular dementia, and Alzheimer's dementia can be effectively treated or prevented.

The disclosure relates to the discovery that certain cerebrovascular disorders in humans who exhibit seemingly normal intracranial pressure (ICP) and do not exhibit hydrocephalus can be alleviated or prevented by reducing ICP in the human. Disorders of this type are herein designated normotensive, nonhydrocephalus tenso-responsive cerebrovascular disorder (NNTCDs). The disclosure describes methods of relieving head pain and other symptoms of NNTCDs, for example by withdrawing cerebrospinal fluid (CSF) from the subarachnoid space of a human or by administering a pharmaceutical agent that modulates CSF production, uptake, or both. Methods of assessing whether a human is afflicted with one or more NNTCDs are also described. The disclosure describes numerous pharmaceutical compositions suitable for administration to humans afflicted with NNTCDs to alleviate or prevent such disorders. Such compositions can, for example, include both a CSF-reducing agent and a symptomatic (e.g., head pain) relief agent.

The invention discloses a system for monitoring treatment of ischemic cerebrovascular disorder on the basis of image information. The system comprises: a clinical image processing module, a before-treatment and after-treatment image analysis module, and a treatment monitoring module. The clinical image processing module is used for performing importing, saving, format converting, grouping and image normalizing to clinic cerebral blood flow perfusion images, and generating cerebral blood flow perfusion templates; the before-treatment and after-treatment image analysis module is used for performing contrastive analysis to cerebral blood flow perfusion sequential images before clinical treatment and after clinical treatment, computing and obtaining quantitative parameters for therapeutic effect evaluation; the treatment monitoring module is used for selecting the quantitative parameters, establishing the relation between the quantitative parameters and traditional clinic assessment of recovery level, generating a specialist judging module of therapeutic effect evaluation, and monitoring the treatment process for ischemic cerebrovascular disorder on the basis of the specialist judging module.

The invention discloses a N, N'-difluoro-substituted-phenyl derivative of 4-methoxyl-1, 3-phenyldiamide, and relative application, while the compound can restrain platelet aggregation activity, to treat the diseases as cardiac infarction, cerebrovascular disorder, pulmonary embolism and atherosclerosis, with antipyretic, analgesia, and antiphlogistic activities.

The present invention relates to a hemorrhage reducing agent in cerebrovascular disorder containing a poly (ADP-ribose) polymerase inhibitor (PARP inhibitor). The PARP inhibitor provides an inhibitory effect of vascular endothelial cell disorder so that it may reduce hemorrhage in cerebrovascular disorder. In addition, the PARP inhibitor inhibits the hemorrhage that is concerned about in thrombolytic agent use by using together with a thrombolytic agent, and an effect of extending therapeutic time window of a thrombolytic agent may be further expected. Furthermore, the PARP inhibitor can be a safe hemorrhage reducing agent with fewer side effects because it does not affect the blood coagulation system and the fibrinolytic system.

Disclosed are pyrimidinone compounds having formula (I), a preparation and use thereof. The compounds are inhibitors of HMG-CoA reductase, and therefore have antivirus activities and are useful for preventing and treating cardiovascular and cerebrovascular disorders, senile dementia, diabetes mellitus, osteoporosis and tumors, and enhancing immune functions in a subject, and especially useful for treating diseases associated with hyperlipaemia.

The invention relates to dried fish floss of tea flavor and a preparation method of the dried fish floss. The dried fish floss comprises the following raw materials in parts by weight: 800-900 parts of fish, 40-50 parts of tea leaves, 40-50 parts of common salt, 50-60 parts of table vinegar, 50-60 parts of cooking wine, 10-20 parts of brown sugar, 10-20 parts of dark soy sauce, 20-40 parts of ginger powder, 30-50 parts of aniseed, 40-50 parts of common fennel, 8-10 parts of cassia bark, 5-8 parts of clove and 3-5 parts of nutmeg. The fishy smell of the dried fish floss is effectively reduced by the tea leaves added into the dried fish floss of tea flavor, and the special tea flavor is achieved, so that the dried fish floss has a unique taste; and the dried fish floss of tea flavor is rich in protein and nutriment and mineral substances and has the effects of lowering blood sugar, blood fat and blood pressure after being eaten for long time, so that the cardiovascular and cerebrovascular diseases are prevented. In addition, due to addition of different types of tea leaves, the dried fish floss has different tastes, different nutrients and effects and can be eaten by different crowds in different seasons, so that the nutrition of the dried fish floss is greatly improved, and the popularization and the application of the dried fish floss are expanded.

The invention discloses a medicine composition for ischemic diseases, which comprises the following raw materials by weight portion: 5 to 15 portions of radix astragali, 2 to 8 portions of Salvia miltiorrhiza, 1 to 5 portions of ligusticum wallichii, 1 to 5 portions of safflower and 1 to 3 portions of earthworms. The invention simultaneously discloses application of the medicine composition in preparing pharmaceutical preparation for treating ischemic cerebrovascular disorder, application of the medicine composition in pharmaceutical preparation for treating ischemic cardiomyopathy, and application of the medicine composition in pharmaceutical preparation for treating ischemic enteropathy. The medicine composition can be used for preventing and treating ischemic diseases such as ischemic cerebrovascular disorder, ischemic cardiomyopathy and ischemic enteropathy, and can also be used for treating coronary heart disease, arteriosclerosis and mesenteric vein embolism. The medicine composition has strong pertinence and obvious medicine effect, and provides more application selections for clinical medication.

The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.

The invention discloses a breviscapin-containing oral cavity spraying agent, which is mainly prepared from the following components in percentage by mass: 5 to 10 percent of breviscapin, 3 to 6 percent of cosolvent, 0.1 to 1.5 percent of sorbefacient, 0.1 to 0.3 percent of preservative, 0.02 to 0.08 percent of flavoring agent and the balance of purified water. A preparation method of the oral cavity spraying agent comprises the following steps of: crushing the breviscapin, adding ethanol, heating for refluxing, and filtering and concentrating; after heating, regulating the pH value, standing, filtering, regulating the pH value of filter liquor, standing and performing suction filtration; precipitating with ethanol and washing with the water; adding methanol and active carbon, heating, filtering, concentrating the filter liquor, crystallizing, and washing and drying to obtain a coarse product; regulating the pH value of the coarse product, heating, centrifuging, allowing the filter liquor to pass through resin, eluting, concentrating the filter liquor under reduced pressure, performing suction filtration, regulating the pH value, standing and performing suction filtration to obtain precipitates, and washing and drying to obtain the breviscapin; and dissolving the breviscapin in the components, stirring uniformly, and filtering to obtain the spraying agent. The oral cavity spraying agent has quick response, high bioavailability and good effect of treating cardiovascular and cerebrovascular diseases, and is convenient to carry.

An effective agent for treating ischemic disease, the agent containing human granulocyte colony-stimulating factor (human G-CSF) as an active ingredient is disclosed. By administering this therapeutic agent, an effective therapy particularly for obstructive arteriosclerosis is provided which can eliminate drawbacks with conventional therapies, such as kinesitherapy, pharmacotherapy, and revascularization, and recently proposed therapies, such as gene therapy and intramuscular transplantation of bone marrow cells. Furthermore, the therapeutic agent can be used as an agent for treating ischemic disease, such as ischemic cerebrovascular disorder or ischemic heart disease.